BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Science Translational Medicine
Florence Coussy, Rania El-Botty, Sophie Château-Joubert, Ahmed Dahmani, Elodie Montaudon, Sophie Leboucher, Ludivine Morisset, Pierre Painsec, Laura Sourd, Léa Huguet, Fariba Nemati, Jean-Luc Servely, Thibaut Larcher, Sophie Vacher, Adrien Briaux, Cécile Reyes, Philippe La Rosa, Georges Lucotte, Tatiana Popova, Pierre Foidart, Nor Eddine Sounni, Agnès Noel, Didier Decaudin, Laetitia Fuhrmann, Anne Salomon, Fabien Reyal, Christopher Mueller, Petra Ter Brugge, Jos Jonkers, Marie-France Poupon, Marc-Henri Stern, Ivan Bièche, Yves Pommier, Elisabetta Marangoni
DOI
10.1126/scitranslmed.aax2625
Abstract

Triple-negative breast cancer xenografts with BRCAness, high expression of SLFN11, and RB1 loss are highly sensitive to topoisomerase I inhibitors.

Teams / Core Facilities
Members